An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets.

Trial Profile

An Open-label, Partially Randomized, 5-way Crossover Study in Healthy Volunteers to Assess the Relative Bioavailability of 100 and 150 mg Fostamatinib Tablets Compared With 50 mg Fostamatinib Tablets.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2011

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T cell lymphoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 27 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
    • 16 Aug 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top